Lucentis first VEGF inhibitor approved for DME in Japan
This article was originally published in Scrip
Executive Summary
Novartis's antibody fragment product Lucentis (ranibizumab) has become the first VEGF-targeting therapy to be approved in Japan for the treatment of diabetic macular edema (DME).